Key result
Dapagliflozin proves cost-effective versus standard care alone for HFrEF at under ~$84,000 per QALY.
Why the study?
It was unclear whether adding dapagliflozin to standard care therapy is cost-effective in heart failure with reduced ejection fraction.
Is dapagliflozin plus standard care therapy cost-effective compared to standard care therapy alone in patients with HFrEF?
Systematic Review (n=10)
Is dapagliflozin plus standard care therapy cost-effective compared to standard care therapy alone in patients with HFrEF?
Dapagliflozin added to standard care is a cost-effective treatment strategy for HFrEF across various international healthcare systems.
Supports dapagliflozin adoption in HFrEF care pathways; confirms economic value across international systems.
OBJECTIVES: This study was aimed to systematically review published economic studies to determine whether dapagliflozin, a sodium-glucose co-transporter inhibitor, plus standard care therapy (SCT) is cost-effective in heart failure with reduced ejection fraction (HFrEF). METHOD: We searched relevant keywords in PubMed, Scopus, Web of science, and Google Scholar to find related articles. Costs, QALYs, ICERs were extracted from eligible studies. RESULTS: Ten studies finally included in the systematic review. The results of quality assessment of the study showed that a reasonable quality of all studies. Incremental QALYs were in favor of dapagliflozin plus SCT treatment regimen. In all the studies, the incremental costs per QALY was below the willingness-to-pay (WTP) threshold with the exception of one study in United Kingdom which the ICER and WTP were $83,650 and $50,000. All the studies determined the National Health Care perspective. The highest and lowest ICERs were $83,650 and $1991 per QALY in United Kingdom and Thailand, respectively. CONCLUSION: Results of cost-effectiveness analyses showed that adjunct dapagliflozin plus SCT is cost-effective compared to SCT alone despite the additional costs of the drug. Finally it can be concluded that dapagliflozin is a worldwide cost-effective as an adjunct medicine in HFrEF management.
No takes yet. Share an insight, caveat, or question.
Mohammadnezhad et al. (2022) conducted a systematic review in Heart failure with reduced ejection fraction (HFrEF) (n=10). Dapagliflozin plus standard care therapy vs. Standard care therapy alone was evaluated on Incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY). Dapagliflozin plus standard care therapy is cost-effective compared to standard care alone for the management of heart failure with reduced ejection fraction, with ICERs ranging from $1,991 to $83,650 per QALY.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: